Olympus expands iTind device availability across major APAC markets
Olympus Corporation of Asia Pacific Limited has announced expanded availability of its iTind™ device across major Asia-Pacific markets. This minimally invasive treatment for benign prostatic hyperplasia (BPH) will soon launch in Korea, making it available in six APAC markets, supporting Olympus’s commitment to improving urological health outcomes.
Minimally invasive solution addressing common male health concern
The iTind procedure offers a temporary implantable nitinol device that relieves lower urinary tract symptoms (LUTS) secondary to BPH without requiring medications, permanent implants, or tissue removal. Already established in the United States and Europe, the expanded APAC availability represents a significant advancement in regional access to innovative urological treatments.
BPH affects a substantial proportion of men over 50, with risk increasing with age. Common symptoms include frequent urination with urgency, weak urinary stream, and nocturia. The iTind procedure provides a rapid intervention that can be performed in outpatient settings under local anaesthesia, potentially reducing hospital resource demands.
“With our upcoming launch in Korea, achieving wider availability of the iTind device in APAC is an important milestone for physicians and patients in our region,” said Daisuke Goto, Head of Surgical Business at Olympus APAC. “We’re excited to provide increased access to a minimally invasive outpatient BPH procedure for suitable patients.”
Clinical recognition and implementation support
The iTind procedure gained significant clinical validation when it was included in the American Urological Association (AUA) clinical practice guideline for management of LUTS attributed to BPH in September 2023. In the United States, two new Category I CPT codes for the iTind procedure became effective January 2025, enabling standardised billing across all service sites.
To facilitate successful clinical implementation, Olympus has developed a comprehensive training programme supporting physicians in incorporating the iTind procedure into their clinical practice. This structured approach aims to optimise patient outcomes and procedural success rates.
Technical innovation in prostatic treatment
The iTind device functions through temporary implantation of a nitinol device that reshapes the prostatic urethra. This innovative approach improves urinary flow without permanent anatomical alteration, representing an advancement in minimally invasive urological interventions.
The device will be available in Thailand, Australia, Hong Kong, Singapore, India, and Korea, significantly expanding access to this treatment modality throughout the Asia-Pacific region.
Olympus continues its market development efforts for the iTind solution, working to provide more patients and clinicians with access to this novel procedure while strengthening care pathways and elevating standards of care for BPH patients.
- For more information, visit: https://www.olympus-global.com
